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Abstract
BACKGROUND: Dyslipidemia is a medical condition that refers to an abnormal of blood lipids level, most common 
is hyperlipidemia. Elevation of blood lipid such as cholesterol, triglycerides, low-density lipoprotein (LDL) cholesterol, 
or a low high-density lipoprotein (HDL) cholesterol level induces disturbance of endothelial function. Endothelial 
dysfunction in dyslipidemia is in large part due to a reduced bioavailability of nitric oxide (NO) which is synthesized 
by endothelial NO synthase (eNOS) which will trigger the development of atherosclerosis, and increases the risk of 
coronary heart disease (CHD).
AIM: This study aims to determine the relationship of lipid profiles of dyslipidemia with eNOS levels in CHD patients.
MATERIALS AND METHODS: This study design was a cross-sectional study. The sample in this study was 26 
patients which diagnosed as CHD of outpatients in the department of cardiology of a regional general hospital and 
fulfilled the inclusion and exclusion criteria. Fifteen healthy individuals who come for the general check-up were 
included as a control group. Blood samples were collected for measurements of eNOS levels and lipid profiles that 
carried out according to laboratory standards. Statistical analyses were conducted using analysis of variance and 
Shapiro–Wilk test.
RESULTS: The results of this study showed that eNOS levels in the group of CHD patients (24.174 ± 7.136 ng/ml) 
were significantly lower (p < 0.05) than those in the control group (72.092 ± 30.065 ng/ml). The mean of triglycerides 
and HDL levels has a weak correlation with the level of eNOS (p > 0.05). The mean of LDL level has moderately 
positive correlation with eNOS, while cholesterol has a moderate negative correlation with the level of eNOS (p > 
0.05).
CONCLUSION: This study concluded that high cholesterol levels and low HDL levels in dyslipidemia condition were 
correlated with eNOS, which has a protective function in CHD.
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Introduction
Coronary heart disease (CHD) is a result 
of coronary artery disease (CAD), leading cause of 
death and disability worldwide. The prevalence of 
CHD is expected to increase in the coming years [1]. 
CHD refers to a narrowing of the coronary arteries, 
the blood vessels that supply oxygen and blood to the 
heart. This is usually caused by atherosclerosis which 
is a buildup of plaque inside the artery wall that can 
start in childhood and may be well advanced by middle 
age [2], [3]. The plaque first grows within the walls of 
the coronary arteries and continues to develop until the 
blood flow to the heart’s muscle decreases. This can 
be chronic, by the narrowing of the coronary artery and 
reduce of the blood supply to the heart muscle, which 
may lead to prevent the heart muscle from receiving 
enough oxygen, referred as myocardial ischemia, or it 
can be acute, due to a sudden rupture of a plaque and 
formation of a thrombus or blood clot, that could lead to 
heart attacks [4], [5].
CHD is caused by the interplay of genetic and 
environmental factors, the effects of which are mainly 
mediated through cardiovascular risk factors. There are 
many risk factors for CHD that can be controlled such 
as high blood pressure, high blood cholesterol levels, 
as well as the effects of related factors such as blood 
triglyceride, low-density lipoprotein (LDL) cholesterol 
level, and high-density lipoprotein (HDL) cholesterol 
levels, diabetes mellitus, overweight or obesity, lack 
of physical activity, smoking, unhealthy diet, and 
psychosocial factors. Those cannot be controlled such 
as age, sex, family history, and race. The multiple 
interrelated factors seem responsible for occurrence of 
CHD [6], [7].
Atherosclerosis is a lipoprotein-driven disease 
that leads to plaque develops in the arterial wall 
characterized by accumulation of lipids, fibrous, and 
inflammatory molecules. Lipoproteins are complex 
plasma particles containing a core of cholesterol 
esters and triglycerides surrounded by free cholesterol, 
phospholipids, and apolipoproteins. The size, structure, 
and apolipoprotein content of the lipoproteins, 
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namely, chylomicrons, very LDL, intermediate-density 
lipoprotein, LDL, HDL, and lipoprotein a, crystallize into 
individualized atherosclerotic risk profiles for the specific 
lipoprotein. Medical condition refers to an abnormal 
level of blood lipids levels known as dyslipidemia. The 
term describes a wide range of conditions, the most 
common forms of dyslipidemia involve: High levels 
of LDL, low levels HDL, high levels of triglycerides, 
and high cholesterol, which refers to high LDL and 
triglyceride levels [6], [8].
High levels of triglycerides and LDL 
cholesterol (LDL-C) damage vascular endothelial 
cells and their functions. Efflux of LDL cholesterol to 
the subendothelial space, which can then be modified 
and oxidized by various agents promotes monocyte 
adhesion and migration to the subendothelial 
space. Monocytes differentiate to macrophages 
and become foam cells that have pro-inflammatory 
functions, including the release of cytokines such as 
interleukins and tumor necrosis factor. Endothelial 
dysfunction is mediated through several diverse 
mechanisms that include increased oxidative stress 
and pro-inflammatory responses [9], [10]. Non-HDL 
cholesterol contributes to impairment of nitric oxide 
(NO) bioavailability due to increased production of 
reactive oxygen species and inhibition of endothelial 
NO synthase (eNOS) activity that leads to endothelial 
dysfunction. Disruption of endothelial function is 
considered a key event in the development and 
progression of atherosclerosis [11].
eNOS is a constitutively expressed enzyme 
that modulates endothelial functions, expressed mainly 
in the endothelium of large arteries which decrease in 
smaller arteries and disappear in capillary. eNOS is 
primarily responsible for the generation of NO in the 
vascular endothelium. NO produced by eNOS in the 
vascular endothelium plays crucial roles in regulating 
vascular tone, cellular proliferation, leukocyte adhesion, 
and platelet aggregation. Therefore, a functional eNOS 
is essential for a healthy vascular system [11], [12]. 
Elevated levels of LDL decrease the bioavailability of 
endothelium-derived NO, reduce NO production in part 
by increasing the interaction between caveolin-1 and 
eNOS, and downregulate endothelial eNOS [10].
The purpose of this study was to determine 
whether there is an association between dyslipidemia 
(triglyceride, HDL cholesterol [HDL-C], LDL-C, and total 
cholesterol) with eNOS levels in CHD patients.
Materials and Methods
The design of this study was cross-sectional 
study. Participants were enrolled in this study, which 
were the outpatient in the department of cardiology of a 
regional general hospital in Padang.
Samples
Subjects in this study were 26 patients in 
the age of 35–55 years old, diagnosed with CHD by 
the cardiologist clinically with electrocardiogram and 
laboratory confirmation. All subjects fulfill the inclusion 
and exclusion criteria, such as a history of malignancies, 
infectious diseases, and other autoimmune diseases. 
Fifteen healthy individuals who come for the general 
check-up were included as a control group. Venous 
blood samples were collected after a 12 h fast by certified 
technicians using standardized venipuncture procedure 
from the patients cubital veins for the measurement of 
lipid profile and eNOS levels.
Examination of serum lipid profile
Serum was measured for lipids panel by 
an enzymatic colorimetric method using reagents of 
chemistry products on automated clinical chemistry 
analyzers. Based on laboratory standard, dyslipidemia 
was confirmed when the levels of triglyceride were 
lower than 150 mg/dl, LDL below 100 mg/dl, HDL above 
50 mg/dl, and total cholesterol lower than 200 mg/dl.
Blood were collected into a glass tube, placed 
upright, and allowed for 45 min at room temperature 
and then centrifuge the blood samples at 1500× g for 
30 min at 4°C. Sample was analyzed using Abbott 
Architect instrument, enzymatically and simultaneously 
using reagents from the same manufacturer. Place a 
100 ul aliquot of sample into the sample cups on the 
instrument carousel using a transfer pipet. Arrange the 
samples on the carousel in the order in which they are 
to be analyzed, as determined from the download file. 
The measurements were programmed by downloading 
the specimen ID numbers and test codes for a lipid 
panel includes total cholesterol, measures all the 
cholesterol in all the lipoprotein particles; HDL-C, 
measures the cholesterol in HDL particles; LDL-C, 
calculates or measures the cholesterol in LDL particles; 
and triglycerides, measures all the triglycerides in all 
the lipoprotein particles total cholesterol, triglyceride, 
HDL-C, and direct HDL-C, as appropriate in machine 
readable form. The results are printed on the Architect 
printout and also sent in real time to computer text files 
on a dedicated computer.
Measurement of eNOS levels
The level of eNOS was measured using 
monoclonal antibody against eNOS for ELISA methods. 
All measurements were following the manufacturer’s 
protocol, carried out in the Biomedical Laboratory of 
the Medical Faculty, Andalas University. Human eNOS 
ELISA kit from Bioassay Technology Laboratory (Abcam 
E0908 Hu) is an in vitro enzyme-linked immunosorbent 
assay for the measurement of human pan-eNOS and 
total eNOS. The eNOS antibody has been coated onto 
a 96-well plate. Blood samples were centrifuged for 20 
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min at 1000× g at 4°C, and then, 40 ul serum of blood 
samples were pipetted into the wells and eNOS present 
in a sample is bound to the wells by the immobilized 
antibody. The wells were washed and 10 ul mouse 
anti-eNOS antibody is used to detect pan eNOS. After 
washing away unbound antibody, 50 ul HRP-conjugated 
anti-mouse IgG is pipetted to the wells. The wells were 
again washed, a 90 ul TMB substrate solution was 
added to the wells and color develops in proportion to 
the amount of eNOS or eNOS bound. The stop solution 
changes the color from blue to yellow, and the intensity 
of the color is measured at 450 nm.
Ethical clearance
This study involved human subjects so that it 
requires a statement of informed consent. All patients 
and healthy controls in the study provided written 
informed consent. The study protocol and all procedures 
were approved by the Institutional Review Board of 
Faculty of Medicine, Andalas University no.708/KEP/
FK/2019, and comply with the Helsinki Declaration of 
1975, as revised in 2000.
Statistical analysis
The data analysis was done in line with study 
objectives. Values were expressed as mean ± standard 
deviation, univariate and multivariate linear regression 
analyses were performed to evaluate the association 
of variables. Normally distributed variables were 
analyzed using one-way analysis of variance. Non-
normally distributed variables were analyzed using 
Mann–Whitney or Kruskal–Wallis tests. The Student’s 
t-test was used for parametric data to compare the 
means of quantitative variables between two groups. 
A Chi-square test was used to compare frequencies 
across groups. Spearman’s correlation was used 
for non-normally distributed variables. p = 0.05 
was considered to indicate a statistically significant 
difference.
Results
Lipid profiles in the CHD patients, as shown 
in Table 1, show that the average triglyceride levels 
were higher than normal levels (below 200 mg/dl), 
LDL-C levels were higher than normal levels (below 
100 mg/dl), total cholesterol levels were higher than 
normal levels (150 mg/dl), while HDL-C levels were 
lower than normal levels (above 50 mg/dl).
The results of eNOS levels measurement in 
our study showed that eNOS levels in CHD patients 
(24.174 ± 7.136) were significantly lower than controls 
group (72.092 ± 30.065) (p < 0.05) (Table 2).
Simple linear regression analyses examining 
the relationship between eNOS with lipid profiles of 
dyslipidemia in CHD patients are shown in Figure 1.
Table 2: Average of eNOS levels (ng/ml) in the coronary heart 
disease patients and control group
No. Groups n Mean ± SD p-value
1 CHD 26 24.174 ± 7.136 <0.05
2 Control 15 72.092 ± 30.065
The level of triglycerides has a weak correlation 
with the level of eNOS (p > 0.05) (Figure 1a). High level 
of LDL-C seems to contribute to the levels of eNOS, 
although was not significant (p > 0.05) (Figure 1b). The 
results show that low level of HDL-C may decrease the 
level of eNOS, although was not significant different 
(p > 0.05) (Figure 1c). This result shows that high of 
total cholesterol levels are associated with significantly 
lower level of eNOS (p < 0.05) (Figure 1d).
Discussion
Examination of serum lipid profile
In this study, the number of CHD patients in 
men (57.4%) was more than women (42.3%), and in 
healthy individuals as a control group, men were 60% 
and women were 40%. Both groups were in the age 
range of 35–55 years. Men in the aged 35–54 years 
have a higher prevalence of cardiovascular disease 
than women of the similar age, but the gap tends to be 
narrower in recent years, with the prevalence decreased 
in men and increased in women [13]. Cardiovascular 
disease develops later in women than in men due to 
exposure of endogenous estrogens during the fertile 
period. Estrogens have a regulating effect on lipids 
metabolisms, inflammatory markers, coagulant system, 
and vascular tones [14].
The elevation of total cholesterol, triglyceride, 
or both, or a low HDL-C level called as dyslipidemia 
contributes to the development of atherosclerosis. 
High LDL cholesterol, low HDL cholesterol, high blood 
pressure, family history, diabetes mellitus, smoking, 
being postmenopausal for women and being older than 
45, and obesity for men are traditional risk factors of 
CHD [7]. Dyslipidemia is a major risk factor for CHD. 
Cholesterol level in blood plasma is determined by 
genetic and by consumption of high fat and cholesterol 
in the diet. In individuals at the CHD high risk, 
elevated LDL-C is considered to be the major cause 
of atherosclerosis and CHD. Therefore, the reduction 
Table 1: Triglyceride, LDL cholesterol, HDL cholesterol, and 
total cholesterol levels in patients with CHD (n = 26) in compare 
to normal standard levels
No. Lipid profile CHD (mg/dl) Normal (mg/dl)
1 Triglycerides 211.50 ± 55.53 <200
2 LDL 136.76 ± 29.39 <100
3 HDL 39.08 ± 10.19 >50
4 Cholesterol 244.03 ± 67.99 <150
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of LDL-C in these individuals may reduce the risk for 
CHD.
Other factors such as obesity and physical 
inactivity contribute to an elevation of cholesterol. 
The LDL-C is the predominant cholesterol-carrying 
lipoprotein and is considered to be the main atherogenic 
lipoprotein, in which LDL-C levels are closely correlated 
with CHD risk. Therefore, the high LDL-C levels than 
normal standard levels are a risk factor for CHD. 
In contrast, a high HDL-C level is considered to be 
protective against CHD. Elevated triglyceride levels also 
are associated with increased CHD risk [6], [15]. A study 
of Orozco et al. [16] found that HDL-C total/HDL-C and 
triglycerides/HDL-C ratio were associated with a higher 
population attributable risk for cardiovascular disease.
Measurement of eNOS levels
High level of lipids in the blood is physical and 
biochemical injury to the endothelium of the coronary 
artery, leads to oxidative stress, eNOS uncoupling, 
and endothelial dysfunction. Vascular oxidative 
stress can be reduce and disrupt eNOS functionally. 
Low level of eNOS affects to NO production and 
function or bioavailability, resulting in increased 
vascular contractions to vasoconstrictors. Therefore, 
decrease of endothelial NO function or increase 
degradation of NO is associated with cardiovascular 
disorders including atherosclerosis as the base for the 
occurrence of CHD. The important function of eNOS is 
to keep blood vessels dilated, control blood pressure, 
vasoprotective, and anti-atherosclerotic effects. 
Although there is no evidence that eNOS is a “disease 
gene,” many cardiovascular risk factors lead to induce 
Figure 1: Correlation between thelial nitric oxide synthase with (a) triglyceride, (b) low-density lipoprotein, (c) high-density lipoprotein, 
(d) cholesterol
dc
ba
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oxidative stress production and cause endothelial 
dysfunction [17].
Experimental and clinical studies provide 
evidence that the dysfunctional eNOS/NO pathway 
and defects of endothelial NO function are associated 
with major cardiovascular risk factors such as 
hyperlipidemia, also have a predictive value for 
atherosclerotic disease progression, and as an early 
marker for various cardiovascular disorders [12]. 
The high levels of triglyceride in the group of CHD 
patients were not contribute to the level of eNOS. The 
change of HDL-C and HDL-C levels is well-established 
independent risk factors for cardiovascular disease, 
while triglycerides remain controversial. Circulating 
triglycerides level has been studied as a risk factor for 
cardiovascular events. Clinical trial has been done by 
Kajikawa et al. [18] suggested that triglycerides are an 
independent predictor of endothelial function. Lowering 
circulating triglyceride levels may improve endothelial 
function, leading to a decrease in cardiovascular 
events.
The LDL-C levels have moderately positive 
correlation with eNOS (Figure 1b). High LDL-C that 
impairs the capacity of NO production is an early step 
in atherogenesis. A mechanism of endothelial toxicity of 
LDL-C that alters the activity of the endothelial isoform 
of NO synthase (eNOS) involves the transcriptional 
activation of the gene encoding caveolin-1, acts 
as a negative regulator of eNOS. Treatment with 
the inhibitors of cholesterol synthesis abrogates 
caveolin-1 upregulation and restores eNOS activity in 
hypercholesterolemic mice [19].
The level of HDL has a weak correlation with 
the level of eNOS (Figure 1c). High-density lipoprotein 
cholesterol has pleiotropic effects including antioxidant, 
anti-apoptotic, anti-inflammatory, anti-thrombotic, or 
anti-proteolytic properties that account for endothelial 
protective action. HDL-C inhibits oxidation by the 
decrease in ROS production and has been shown to 
inhibit apoptosis of endothelial cells induced by different 
stimuli such as oxLDL and TNF-α. HDL isolated from 
patients with CAD was shown to have a reduced 
potential to activate eNOS [20].
The level of total cholesterol has a moderately 
negative correlation with eNOS level (Figure 1d). 
Cholesterol is recognized as a major cause of 
macrovascular disease. The mechanism by which 
serum cholesterol elevations cause cardiovascular 
disease is not completely understood. Impaired 
endothelium-dependent vasodilation associated 
with elevated cholesterol levels could represent one 
such mechanism. Vascular endothelial dysfunction 
related to reduce of NO availability which promotes 
mechanism of arteriosclerosis. There are non-
pharmacological and pharmacological therapies 
to repair vascular endothelial. These therapies are 
intended to increase eNOS activity and NO release, 
inhibit NO degradation [21].
Dyslipidemia, which characterized by elevated 
of triglycerides, total cholesterol, and LDL-C levels, or 
levels of HDL-C, is an important risk factor for CHD. The 
change of this lipid levels may trigger the production of 
oxidative stress that related to deregulation of eNOS 
enzymatic activity and inactivation of NO. eNOS that 
plays a role in vascular protection appears to play an 
important role in endothelial dysfunction due to buildup 
of lipid that induces atherosclerosis in CHD.
Our study was conducted on small number 
of samples which was one of the main limitations 
that necessitate careful interpretation of results. 
Considering to the other risk factors for CHD, further 
studies on each risk factor would certainly be more 
conclusive. However, our data confirm the importance 
of eNOS role in dyslipidemia as a risk factor of CHD. 
CHD is an atherosclerotic disease as the result of 
diverse metabolic and immunologic mechanisms by 
the formation of fatty acid plaque. The change of lipids 
level in dyslipidemia, including low levels of HDL, 
high levels of LDL, triglycerides, and cholesterol, may 
trigger the production of oxidative stress that related to 
deregulation of eNOS enzymatic activity and inactivation 
of NO. NO is a signaling molecule that plays a key role 
in the pathogenesis of inflammation and cell activation 
that eventually leads to endothelial dysfunction. 
Endothelial dysfunction plays a key role in the induction 
and progression of atherosclerosis and consequently of 
CHD. Our result confirmed that eNOS was associated 
with the elevated of low-density lipoprotein (LDL) 
cholesterol and the triglyceride concentrations, and a 
decrease in high-density lipoprotein (HDL) cholesterol 
concentration in the blood.
CONCLUSION
This study concluded that high cholesterol 
levels and low HDL levels in dyslipidemia condition 
were correlated with eNOS, which has a protective 
function in CHD. 
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